What does the XARENO study mean for our patients with atrial fibrillation and kidney disease? by CardioCast published on 2022-06-07T09:52:53Z In this podcast, Dr Manesh Patel, Professor Reinhold Kreutz and Dr Andrew Steele discuss the results of the XARENO study and its implications for patients with AF and chronic kidney disease. This group of experts share their insights on how cardiologists and nephrologists can work most effectively together in multi-disciplinary teams to provide optimal care for these patients. The views and opinions expressed throughout this podcast are those of the speakers based on their expertise and do not necessarily reflect those of Bayer AG. Further details: • The paper on the rationale and design of the XARENO study can be found here: https://journals.viamedica.pl/kardiologia_polska/article/view/86346 • The XARENO abstract presented at ACC 2022 is available here: https://www.jacc.org/doi/10.1016/S0735-1097%2822%2901192-5 • The results of XARENO presented at AHA 2020 can be accessed here: https://www.ahajournals.org/doi/10.1161/circ.142.suppl_3.13927 • Further information on the XARENO trial can be found on the clinicaltrials.gov page here: https://clinicaltrials.gov/ct2/show/study/NCT02663076 • The paper on the ANTENNA study can be found here: https://www.sciencedirect.com/science/article/pii/S0167527322001905 • The 2021 ESC guidelines for the diagnosis and management of atrial fibrillation featuring the ABC pathway for AF treatment are available here: https://academic.oup.com/eurheartj/article/42/5/373/5899003 • Find the 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guidelines for the management of patients with atrial fibrillation here: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000665 • The EHRA practical guide on the use of NOACs in patients with atrial fibrillation can be accessed here: https://academic.oup.com/europace/article/23/10/1612/6247378 • For anticoagulant dosing information, see the European labels for apixaban (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf), dabigatran (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf), edoxaban (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf), rivaroxaban (https://www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_en.pdf) and warfarin (https://www.medicines.org.uk/emc/product/3064/smpc) and the Canadian label for rivaroxaban (https://pdf.hres.ca/dpd_pm/00059600.PDF) Shownotes: MA-M_RIV-ALL-1212-1 Recording: MA-M_RIV-ALL-1205-1 Genre Science